(S)-2-methoxy-3-(4-methoxyphenyl)propanoic acid | 875112-27-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: (S)-2-methoxy-3-(4-methoxyphenyl)propanoic acid
• 英文别名: (S)-2-methoxy-3-(4-methoxyphenyl)propionate；(2S)-2-Methoxy-3-(4-methoxyphenyl)propanoic Acid
• CAS: 875112-27-9
• 化学式: C₁₁H₁₄O₄
• 分子量: 210.23
• InChiKey: OGJKUGGZOYNPSS-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (S)-2-methoxy-3-(4-methoxyphenyl)propanoic acid 在 盐酸 作用下， 以 N-甲基吡咯烷酮 、 水 为溶剂， 以92%的产率得到(2S)-3-(4-hydroxyphenyl)-2-methoxypropanoic acid
  参考文献：
  名称：

  PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-SUBSTITUENT-OXY-3-(4-SUBSTITUENT-OXYPHENYL)­PROPIONIC ACID DERIVATIVE

  摘要：

  本发明涉及一种生产具有光学活性的2-取代氧基-3-(4-取代氧基苯基)丙酸衍生物的方法，包括通过酶对2-氧基-3-(4-取代氧基苯基)丙酸进行立体选择性还原，然后将得到的光学活性2-羟基-3-(4'-取代氧基苯基)丙酸根据需要酯化羧基，接着烷基化羟基，必要时去除醚型保护基。本发明可能能够以简单、易操作且具有商业优势的方式高效生产用于合成药物化合物的有用中间体——具有光学活性的2-取代氧基-3-(4-取代氧基苯基)丙酸衍生物。

  公开号：

  EP1801224A1
• 作为产物：
  描述：

  ethyl (S)-2-methoxy-3-(4-methoxyphenyl)propanoate 在 水 、 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 以95%的产率得到(S)-2-methoxy-3-(4-methoxyphenyl)propanoic acid
  参考文献：
  名称：

  Enzyme-mediated synthesis of EEHP and EMHP, useful pharmaceutical intermediates of PPAR agonists

  摘要：

  A new scaleable synthetic route to the title compounds has been developed. The reaction pathway is based on the alpha-chymotrypsin-catalysed hydrolysis of the racemic ethyl 2-ethoxy-3-(p-methoxyphenyl)propanoate or of the racemic ethyl 2-methoxy-3-(p-methoxyphenyl)propanoate to give the corresponding resolved (S)-esters with excellent ee. The acids were easily separated from the (S)-esters by a simple acid-base work-up. The overall yields of 1 and 2 were 16% and 17%, respectively. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2009.10.013

文献信息

• PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-SUBSTITUENT-OXY-3-(4-SUBSTITUENT-OXYPHENYL)­PROPIONIC ACID DERIVATIVE
  申请人：Kaneka Corporation

  公开号：EP1801224A1

  公开（公告）日：2007-06-27

  The present invention relates to a process for producing an optically active 2-substituent-oxy-3-(4-substituent-oxyphenyl)propionic acid derivative which comprises stereoselectively reducing an 2-oxo-3-(4-substituent-oxyphenyl)propionic acid by an enzyme and subjecting the thus-obtained optically active 2-hydroxy-3-(4'-substituent-oxyphenyl)propionic acid to esterification of the carboxyl group according to need, then to alkylation of the hydroxyl group and, if necessary, to deprotection of an ether type protective group. The present invention may make it possible to produce an optically active 2-subsituent-oxy-3-(4-substituent-oxyphenyl)propionic acid derivative, which is useful as intermediates for the synthesis of medicinal compounds, efficiently, in a simple and easy manner, and commercially advantageously.

  本发明涉及一种生产具有光学活性的2-取代氧基-3-(4-取代氧基苯基)丙酸衍生物的方法，包括通过酶对2-氧基-3-(4-取代氧基苯基)丙酸进行立体选择性还原，然后将得到的光学活性2-羟基-3-(4'-取代氧基苯基)丙酸根据需要酯化羧基，接着烷基化羟基，必要时去除醚型保护基。本发明可能能够以简单、易操作且具有商业优势的方式高效生产用于合成药物化合物的有用中间体——具有光学活性的2-取代氧基-3-(4-取代氧基苯基)丙酸衍生物。
• Highly enantioselective hydrogenation of α-oxy functionalized α,β-unsaturated acids catalyzed by a ChenPhos–Rh complex in CF₃CH₂OH
  作者：Lin Yao、Jialin Wen、Shaodong Liu、Renchang Tan、Noel Marie Wood、Weiping Chen、Shengyong Zhang、Xumu Zhang

  DOI：10.1039/c5cc09089j

  日期：——

  A Chenphos–Rh complex is demonstrated to be a highly efficient catalyst for asymmetric hydrogenation of α-oxy functionalized α,β-unsaturated carboxylic acidsviaan ionic interaction between the ligand and the substrate.

  一种Chenphos-Rh络合物被证明是α-氧基化α，β-不饱和羧酸的不对称加氢反应的高效催化剂，通过配体和底物之间的离子相互作用。
• Process for Producing Optically Active 2-Substituent-Oxy-3-(4-Substituent-Oxyphenyl) Propionic Acid Derivative
  申请人：Honda Tatsuya

  公开号：US20090029429A1

  公开（公告）日：2009-01-29

  The present invention relates to a process for producing an optically active 2-substituent-oxy-3-(4-substituent-oxyphenyl)propionic acid derivative which comprises stereoselectively reducing an 2-oxo-3-(4-substituent-oxyphenyl)propionic acid by an enzyme and subjecting the thus-obtained optically active 2-hydroxy-3-(4-substituent-oxyphenyl)propionic acid to esterification of the carboxyl group according to need, then to alkylation of the hydroxyl group and, if necessary, to deprotection of an ether type protective group. The present invention may make it possible to produce an optically active 2-substituent-oxy-3-(4-substituent-oxyphenyl)propionic acid derivative, which is useful as intermediates for the synthesis of medicinal compounds, efficiently, in a simple and easy manner, and commercially advantageously.

  本发明涉及一种制备光学活性的2-取代氧基-3-(4-取代氧基苯基)丙酸衍生物的方法，其包括通过酶对2-氧代-3-(4-取代氧基苯基)丙酸进行立体选择性还原，然后对得到的光学活性的2-羟基-3-(4-取代氧基苯基)丙酸根据需要进行羧基酯化，然后进行烷基化羟基，如有必要，则进行醚型保护基的去保护。本发明可以使得在简单、易行和商业上有优势的情况下高效地制备出用于合成药物化合物的光学活性的2-取代氧基-3-(4-取代氧基苯基)丙酸衍生物。
• New stereospecific synthesis of Tesaglitazar and Navaglitazar precursors
  作者：Elisabetta Brenna、Claudio Fuganti、Francesco G. Gatti、Fabio Parmeggiani

  DOI：10.1016/j.tetasy.2009.10.027

  日期：2009.12

  A new synthetic route of to pharmaceutical intermediates (S)-1a-b and (S)-14 is reported. The reaction pathway is based on the baker's yeast-mediated reduction of the alpha-alkoxy cinnamaldehydes 9a-c to give the corresponding (S)-alcohols in good yields and excellent ee. (C) 2009 Elsevier Ltd. All rights reserved.
• Enzyme-mediated synthesis of EEHP and EMHP, useful pharmaceutical intermediates of PPAR agonists
  作者：Elisabetta Brenna、Claudio Fuganti、Francesco G. Gatti、Fabio Parmeggiani

  DOI：10.1016/j.tetasy.2009.10.013

  日期：2009.11

  A new scaleable synthetic route to the title compounds has been developed. The reaction pathway is based on the alpha-chymotrypsin-catalysed hydrolysis of the racemic ethyl 2-ethoxy-3-(p-methoxyphenyl)propanoate or of the racemic ethyl 2-methoxy-3-(p-methoxyphenyl)propanoate to give the corresponding resolved (S)-esters with excellent ee. The acids were easily separated from the (S)-esters by a simple acid-base work-up. The overall yields of 1 and 2 were 16% and 17%, respectively. (C) 2009 Elsevier Ltd. All rights reserved.